͵͵

Lipid News

Don’t game the system — be the system

Binks Wattenberg
Oct. 1, 2016

Who here is tired of exchanging tales of woe about grants not funded? Most of us, I suspect. Here I will describe how a group came together to develop a plan to give lipid-related grants a fair shake while we work to increase overall funding.

Lipid researchers often feel that their grants get dinged because of a lack of expertise in lipid biology in study sections. We know that when you are an expert in a field, you have a greater appreciation for the contributions that a particular grant can make to advance the field. With this in mind, colleagues and I started an initiative to ensure that grants with a lipid focus get the expert review that they (and all grants, really) deserve.

It is lost in the mists of time exactly when and where the idea nucleated, who was there, and why I could never get the hang of the secret handshake. But in time, a notion congealed — like a vat of warm triglyceride cooling in the breeze — that instead of kvetching about the lack of lipid expertise on the study sections, the lipid community could have a role in helping provide that expertise to the National Institutes of Health and other granting bodies.

And so the Lipid Research Division, or LRD (pronounced “lard,” of course), was born. Here, I will focus on how we have leveraged the LRD to help with grant review. The effort showcases how the LRD serves as an important voice for the lipid community within the ͵͵ and ͵͵ Biology.

The first step was to establish a membership. The staff of the ASBMB has been phenomenal throughout this process, both in welcoming the LRD as part of the ASBMB and in providing the information technology expertise and access to their membership database that were essential. We queried the ASBMB membership for interest in joining the LRD and also included non-ASBMB members to lasso them into the ASBMB fold. We established an LRD membership list of several hundred members.

The next step was crucial. We engaged with staffers at the Center for Scientific Review at the NIH. Our pitch was simple: We want to help provide expertise, not push for more funding for lipid grants.

Several LRD steering committee members already had informally spoken with study-section scientific review officers to see if they were receptive to getting suggestions for lipid-centric reviewers. The response was overwhelmingly positive. SROs have so much to deal with. Imagine having to tell a study section full of caffeine junkies that coffee would no longer be available at the meetings. Horrors! Only slightly less onerous is ensuring that each study section is populated by the requisite expertise to review 80 grants on diverse topics using a variety of techniques. SROs do heroic duty by attending national meetings, going through meeting programs, looking through the literature and querying their contacts. They were glad for the help.

Encouraged, we went right to the top, speaking with Richard Nakamura, who is the director of CSR. He thought the idea was sound and guided us as to the qualifications they look for in reviewers and what information they could use that would help SROs find the expertise they need.

With the help of Ed Marklin, the IT wizard at the ASBMB, we used the awesome power of Survey Monkey to see who in the LRD fit the CRS’s criteria. Close to 50 of the LRD membership had NIH-eligible reviewing experience but currently were not serving. This was a treasure trove of potential lipid expertise. We transmitted the list to one of Nakamura’s advisers at the CSR, Christine Melchior, who since has customized the list for SROs for whom she is responsible.

We are not done. We also are thinking of granting bodies outside of the NIH, such as the National Science Foundation, Department of Defense and disease-specific foundations, that could use our list. We also know there are lipid experts out there who are eluding their NIH duties. We are tracking them down.

Which brings me to my last point, which is about participating in NIH review. The review process is only as good as the reviewers who wade through the grants. If an SRO invites you to review, even though you absolutely do not have the time, make some. Give up sleeping or eating: There is plenty of time for that after you retire. See you at study section. I will bring the coffee.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition weekly.

Learn more
Binks Wattenberg

Binks Wattenberg is a professor in the department of biochemistry and molecular biology at Virginia Commonwealth University and a member of the ASBMB Today editorial advisory board.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Guiding grocery carts to shape healthy habits
Award

Guiding grocery carts to shape healthy habits

Nov. 21, 2024

Robert “Nate” Helsley will receive the Walter A. Shaw Young Investigator in Lipid Research Award at the 2025 ASBMB Annual Meeting, April 12–15 in Chicago.

Quantifying how proteins in microbe and host interact
Journal News

Quantifying how proteins in microbe and host interact

Nov. 20, 2024

“To develop better vaccines, we need new methods and a better understanding of the antibody responses that develop in immune individuals,” author Johan Malmström said.

Leading the charge for gender equity
Award

Leading the charge for gender equity

Nov. 19, 2024

Nicole Woitowich will receive the ASBMB Emerging Leadership Award at the 2025 ASBMB Annual meeting, April 12–15 in Chicago.

CRISPR gene editing: Moving closer to home
News

CRISPR gene editing: Moving closer to home

Nov. 17, 2024

With the first medical therapy approved, there’s a lot going on in the genome editing field, including the discovery of CRISPR-like DNA-snippers called Fanzors in an odd menagerie of eukaryotic critters.

Finding a missing piece for neurodegenerative disease research
News

Finding a missing piece for neurodegenerative disease research

Nov. 16, 2024

Ursula Jakob and a team at the University of Michigan have found that the molecule polyphosphate could be what scientists call the “mystery density” inside fibrils associated with Alzheimer’s, Parkinson’s and related conditions.

From the journals: JLR
Journal News

From the journals: JLR

Nov. 15, 2024

Enzymes as a therapeutic target for liver disease. Role of AMPK in chronic liver disease Zebrafish as a model for retinal dysfunction. Read about the recent JLR papers on these topics.